Billionaire David Einhorn’s 5 Stock Picks with Huge Upside Potential

Page 5 of 5

1. Gain Therapeutics, Inc. (NASDAQ:GANX)

Greenlight Capital’s Stake Value: $1,929,985

Upside Potential as of December 1: 309.09%

Bethesda, Maryland-based Gain Therapeutics, Inc. (NASDAQ:GANX) is a biotechnology company focused on developing new medicines for protein misfolding diseases. Its supercomputer-driven target-based drug discovery platform, “SEE-Tx™,” is a novel approach that uses structural and computational biology to discover previously unidentified allosteric binding sites with high potential for druggability.

On December 1, Gain Therapeutics, Inc. (NASDAQ:GANX) announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders (LSDs), including GM1 gangliosidosis.

Gain Therapeutics, Inc. (NASDAQ:GANX) is also investigating a Parkinson’s disease candidate in a Phase I trial with a completion date expected in H1 2024.

As of Q3 2023, Gain Therapeutics, Inc. (NASDAQ:GANX) was ranked highest on our list of billionaire David Einhorn’s 10 stock picks with huge upside potential. The stock was held by 4 hedge funds with the total shares held by hedge funds valued at $2.3 million. David Einhorn’s Greenlight Capital was its largest hedge fund shareholder with ownership of 0.59 million shares valued at $1.9 million. The stock accounted for 0.10% of the firm’s portfolio.

You may also like to read 10 Best Debt Free Penny Stocks To Buy Now and 11 Most Volatile Stocks Under $5 For Day Trading

Page 5 of 5